Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Serum Biomarkers Predict Women at Risk of Preeclampsia

By LabMedica International staff writers
Posted on 09 Aug 2015
The screening of pregnant women to identify those at risk of preeclampsia may improve the prognosis for the mother and the infant and accordingly, there has been an intense search for the early biomarkers of preeclampsia. More...


Severe preeclampsia can affect the mother by damaging the kidneys, liver and other organs and, in really severe cases, cause seizures and coma. There is often less fluid than normal around the baby and the placenta can be affected, restricting blood flow and nutrients necessary for the baby's growth.

Scientists at the Mexican Institute of Social Security (Mexico City, Mexico) carried out a longitudinal study on 252 pregnant women attending two obstetric referral hospitals. Women visited the hospital once a month until delivery. Fasting blood samples from a peripheral vein were obtained after a 10 hour fast and collected in anti-coagulation vacuum-sealed tubes. Clinical records were assessed after every visit to identify women diagnosed with preeclampsia by the obstetrician responsible for her care, which included systolic blood pressure and diastolic blood pressure measurements.

Biochemical determinations were conducted and asymmetric dimethylarginine (ADMA), homocysteine,(Hcy), and vitamin B6 (VB6) and measured by high-performance liquid chromatography (Waters 600, Milford, MA, USA) , with a fluorescence detector (Model 474) and 4.6 × 250-mm columns (ODS Hypersil, Keystone Scientific; Bellefonte, PA, USA). VB12 was measured by chemiluminescence using commercial kits on the Immulite1000 Systems (Siemens; Erlangen, Germany), and folic acid (FA) was measured in whole blood by the microbiological method.

The team found that of the 252 women in their study, based at two hospitals, 49 in the group who went on to develop preeclampsia had raised levels of ADMA and Hcy a month before onset of the condition. The levels of these two biomarkers were raised regardless of the eventual severity of the preeclampsia. There were no significant differences in the concentrations of Hcy and ADMA between the mild preeclampsia and the severe preeclampsia groups; however, the group with mild preeclampsia exhibited intermediate values between the groups with no complications and with severe preeclampsia. Analysis of deltas demonstrated that ADMA and Hcy increased by 124 ± 27 nmol and 1,177 ± 278 nmol respectively, at one month prior to preeclampsia and such increases did not differ between mild and severe preeclampsia groups.

Mardia Lopez-Alarcon, PhD, the lead author of the study said, “While for most of the women we tested the levels of ADMA and Hcy remained constant throughout pregnancy, these serum biomarkers were clearly raised a month before onset in women who went on to develop pre-eclampsia. Of the other factors we tested, obesity and low levels of folic acid at the start of the pregnancy, as all the mothers received folic acid supplementation, were also independently linked to preeclampsia.” The study was published on July 22, 2015, in the journal BJOG: An International Journal of Obstetrics and Gynaecology.

Related Links:

Mexican Institute of Social Security 
Waters
Siemens



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: New findings indicate that chimeric RNAs, once viewed as cancer byproducts, can also be part of normal physiology with regulatory functions (Image credit: Adobe Stock)

Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease

Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read more

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image: Volition’s Nu.Q NETs test detects markers associated with neutrophil extracellular traps, which are released during NETosis and linked to sepsis and other acute and chronic disorders (Image credit: iStock)

Collaboration Aims to Broaden Access to NETosis-Linked Disease Testing

VolitionRx Limited (Henderson, NV, USA), a multinational epigenetics company, has announced a collaboration with Sysmex Corporation (Kobe, Japan), a global leader in in vitro diagnostics, to optimize Volition’s Nu.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.